Agios Pharmaceuticals, Inc. · TRADEGATE:8AP

Agios Pharmaceuticals, Inc. financial statements

Agios Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue54.0M36.5M26.8M14.2M00117.9M94.4M43.0M69.9M
Cost of revenue6.34M4.17M2.88M1.70M001.32M1.40M00
Gross profit42.5M32.3M17.3M12.5M-18.8M-18.8M116.6M93.0M43.0M69.9M
Research and development339.5M301.3M295.5M279.9M257.0M220.8M214.3M341.3M292.7M220.2M
Selling, general and administrative180.3M156.8M119.9M121.7M121.4M115.1M102.0M114.1M71.1M50.7M
Operating income-472.1M-425.7M-391.5M-389.0M-378.4M-335.9M-316.3M-362.5M-320.8M-201.0M
Depreciation and amortization5.20M5.70M6.60M8.40M8.80M9.40M8.09M7.17M6.43M5.71M
EBITDA-466.9M-420.0M-384.9M-380.6M-369.6M-326.5M-308.2M-355.3M-314.4M-195.3M
Interest expense12.8M836.0K17.8M14.9M16.5M6.12M2.51M
Income before tax-413.8M718.0M-352.1M-231.8M-356.5M-329.3M-301.4M-346.0M-314.7M-198.5M
Income tax-1.02M44.2M00-1.98B7.85M0000
Net income-412.8M673.7M-352.1M-231.8M1.60B-327.4M-411.5M-346.0M-314.7M-198.5M
Earnings per share, basic-7.1211.86-6.33-4.2326.55-4.74-6.86-6.03-6.75-5.07
Earnings per share, diluted-7.1211.64-6.33-4.2326.55-4.74-6.86-6.03-6.75-5.07

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents89.1M76.2M88.2M139.3M203.1M127.4M80.9M70.5M102.7M160.8M
Short-term investments765.3M817.5M688.7M643.9M816.9M445.5M483.9M514.8M321.2M380.6M
Receivables10.6M4.11M2.81M2.21M4.38M25.4M15.3M10.4M3.84M8.31M
Inventory32.9M27.6M19.1M8.49M014.7M7.33M869.0K0-32.3M
Current assets942.1M965.6M833.8M832.8M1.06B636.7M611.7M613.8M445.3M559.9M
Property, plant and equipment10.8M11.7M15.4M23.0M28.9M30.8M31.5M24.3M24.4M25.3M
Goodwill00
Total assets1.30B1.66B937.1M1.24B1.44B853.0M890.7M858.5M614.4M619.1M
Accounts payable18.4M16.6M9.78M18.6M16.7M17.7M21.9M17.9M22.8M17.1M
Current liabilities82.2M81.2M68.0M62.6M59.8M94.4M92.9M93.5M94.9M88.4M
Long-term debt00
Total debt40.2M57.0M72.0M85.7M97.1M105.2M113.7M
Total liabilities104.1M122.2M126.1M137.9M145.8M453.5M250.2M170.9M238.9M260.5M
Shareholders' equity1.19B1.54B811.0M1.10B1.29B399.5M640.5M687.5M375.5M358.6M
Shares outstanding58.4M57.2M55.9M55.0M54.3M69.3M68.4M58.2M48.8M42.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-373.0M-389.8M-296.1M-309.5M-407.3M-290.8M-370.6M-304.4M-285.2M38.6M
Capital spending-4.32M-1.69M-999.0K-4.88M-5.74M-14.1M-12.0M-6.99M-4.63M-9.91M
Free cash flow-377.3M-391.5M-297.1M-314.4M-413.1M-304.9M-382.6M-311.4M-289.9M28.6M
Cash from investing377.2M363.4M239.6M243.3M1.25B75.7M91.4M-273.8M-57.9M-119.3M
Cash from financing8.68M14.4M5.43M2.35M-765.8M261.5M289.6M546.0M285.1M169.8M
Dividends paid-37.3M00
Share buybacks02.68M-802.5M11.3M289.7M546.0M285.1M169.8M
Change in cash12.9M-12.0M-51.1M-63.9M75.7M46.5M10.4M-32.2M-58.0M89.0M